Former Neuralink Exec Launches Organ Preservation Effort
Revolutionizing Organ Preservation: Science Corporation's Ambitious Effort
In a groundbreaking move, Science Corporation, a brain-computer interface startup founded by former Neuralink president Max Hodak, is launching a new division focused on extending the life of human organs. This bold initiative aims to improve upon current perfusion systems, which continuously circulate blood through vital organs when they can no longer function on their own. The technology is used to preserve organs for transplant and as a life-support measure for patients when the heart and lungs stop working, but it's clunky and costly.
The Problem with Current Perfusion Systems
Existing perfusion systems, such as extracorporeal membrane oxygenation (ECMO), are expensive and highly resource-intensive. They cost thousands of dollars per day to run, and patients are tethered to them in the hospital. Consisting of a large circuit of tubes that must be wheeled around on a bedside cart, they require constant monitoring and frequent manual adjustments. Because of their high cost, not every hospital has them.
The Inspiration Behind Science Corporation's Effort
Hodak was inspired to work on organ preservation after reading about the case of a 17-year-old boy in Boston whose lungs had failed due to cystic fibrosis. He was being sustained by a type of perfusion called ECMO, while awaiting a transplant. But after two months on the wait list, he developed a complication that made him no longer eligible for a transplant. His doctors and parents faced the ethical dilemma of keeping him alive on ECMO, which is meant to serve as a short-term bridge. Eventually, the machine's oxygenator began to fail and doctors chose not to replace it. Shortly after, the boy lost consciousness and died.
The Goal: A More Affordable and Portable Solution
Science Corporation's goal is to create a smaller, more portable system that could provide long-term support. They aim to make a system that is not only more affordable but also easier to use, with automatic adjustments and real-time monitoring. This would allow patients to be treated in a more comfortable and convenient setting, reducing the need for hospitalization and the associated costs.
The Technology: A Modular Design with Swappable Components
The company's prototype has integrated sensors to monitor blood oxygenation, flow rate, pressure, and temperature in real time. It also features a modular design with swappable components to support different organs and applications. Close-looped control allows it to make automatic adjustments, where current ECMO machines must be manually controlled.
The Competition: Other Companies Making Automated Perfusion Systems
Science Corporation will be competing against several other companies that make automated perfusion systems for organ transplants. While these devices are becoming more common to help preserve organs outside the body, they remain costly and often require specially trained staff. However, Science Corporation is hoping to make a more affordable option.
The Potential Impact: A World of Swappable Parts
If Science Corporation manages to close the gap between what this technology is fundamentally capable of and how it is being deployed and used in daily practice, it could potentially take us from a world of conventional medicine and many of its very difficult problems to a world of swappable parts. This would be a revolutionary change, allowing patients to receive life-saving treatments in a more comfortable and convenient setting.
The Road Ahead: Challenges and Opportunities
While Science Corporation's effort is ambitious, it also comes with challenges. The company will need to overcome technical hurdles, secure funding, and navigate regulatory requirements. However, if successful, this technology could have a profound impact on the field of medicine, improving patient outcomes and reducing costs.
Conclusion
Science Corporation's effort to revolutionize organ preservation is a bold and ambitious initiative. While there are challenges ahead, the potential impact of this technology is significant. If successful, it could take us from a world of conventional medicine to a world of swappable parts, improving patient outcomes and reducing costs.
Source: https://www.wired.com/story/a-brain-computer-interface-company-is-getting-into-organ-preservation/
